0.630
-0.01 (-0.82%)
| Previous Close | 0.635 |
| Open | 0.605 |
| Volume | 1,102,883 |
| Avg. Volume (3M) | 15,237,042 |
| Market Cap | 75,599,424 |
| Price / Earnings (Forward) | 4.54 |
| Price / Sales | 2.97 |
| Price / Book | 1.13 |
| 52 Weeks Range | |
| Earnings Date | 9 May 2025 - 22 May 2025 |
| Operating Margin (TTM) | -139.14% |
| Diluted EPS (TTM) | -1.43 |
| Total Debt/Equity (MRQ) | 1.93% |
| Current Ratio (MRQ) | 1.62 |
| Operating Cash Flow (TTM) | -170.49 M |
| Levered Free Cash Flow (TTM) | -83.05 M |
| Return on Assets (TTM) | -61.64% |
| Return on Equity (TTM) | -138.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Invivyd, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.25 |
|
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 41.18% |
| % Held by Institutions | 71.29% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Mithril Ii Gp Lp | 31 Dec 2024 | 11,241,580 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 10.00 (HC Wainwright & Co., 1,486.80%) | Buy |
| Median | 9.50 (1,407.46%) | |
| Low | 9.00 (D. Boral Capital, 1,328.12%) | Buy |
| Average | 9.50 (1,407.46%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 0.678 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 26 Mar 2025 | 10.00 (1,486.80%) | Buy | 0.616 |
| 24 Feb 2025 | 10.00 (1,486.80%) | Buy | 1.24 | |
| D. Boral Capital | 20 Mar 2025 | 9.00 (1,328.12%) | Buy | 0.739 |
| 05 Mar 2025 | 9.00 (1,328.12%) | Buy | 1.06 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |